Xortx receives small and medium enterprise status for the european union

Calgary, alberta, april 20, 2022 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce receipt of small and medium enterprise (“sme”) status for the european union (the “eu”). this status is applicable for european medicines agency (“ema”) related interactions and confirmed by the sme office – regulatory science and innovation task force. sme status provides reduced costs to the company as it initiates discussions with the us food and drug administration (“fda”) and ema regarding the upcoming xrx-oxy-301 phase 3 registration trial for xrx-008 and other clinical programs.
XRTX Ratings Summary
XRTX Quant Ranking